Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Perils of Part D

This article was originally published in RPM Report

Executive Summary

The Medicare drug benefit means more federal spending on pharmaceuticals-and more oversight of the industry. Two prominent prosecutors are experienced and ready. The first place they will look: contracting between manufacturers and plans and its influence on the formulary selection process.

You may also be interested in...

Changing of the Guard in Health Care Fraud: An Interview With Michael Loucks

Michael Loucks stepped down as acting US Attorney at the end of 2009, after a career that put him at the center of many of the largest health care fraud prosecutions in the pharmaceutical industry. We spoke to him about what happens next, for industry, for prosecutors-and for him.

The Era of Big Pharma Fraud Cases Is Ending, Former US Attorney Loucks Says, But It May Go Out With A Bang

The pace of whistleblower cases against Big Pharma companies is winding down, former prosecutor says. It may not seem that way, with a full pipeline of pending investigations likely to dominate the headlines for months or even years to come, but Big Pharma is finally coming into compliance. This era may end with a bang: Loucks believes there is significant pressure to exclude a corporation for fraud.

Bextra Settlement Coming Soon: Industry Should Brace for Impact

Record setting $2.3 billion payment is afterthought in context of Pfizer/Wyeth merger, but the Bextra and recent Zyprexa settlement will have far-reaching implications. In economic terms, the first two cases of 2009 exceed the total recoveries of the last 13 pharma marketing settlements. But the big impact may be political: the cases involve a volatile mix of marketing abuses and drug safety

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts